Meanwhile, the BSE Sensex was up 290.72 points, or 0.97%, to 30,223.97. The S&P BSE Small-Cap index was up 122.15 points, or 0.79% to 15,666.78

On the BSE, so far 37.51 lakh shares were traded in the counter, compared with average daily volumes of 10.68 lakh shares in the past one quarter. The stock had hit a high of Rs 56.25 and a low of Rs 48.20 so far during the day. The stock hit a 52-week high of Rs 58.30 on 6 October 2016. The stock hit a 52-week low of Rs 36.95 on 1 February 2017.

The stock had underperformed the market over the past one month till 9 May 2017, sliding 4.27% compared with 1.21% rise in the Sensex. The scrip also underperformed the market in past one quarter, declining 14.02% as against Sensex's 5.81% rise.

The small-cap company has equity capital of Rs 40.93 crore. Face value per share is Re 1.

It may be recalled that Marksans Pharma had announced on 20 February 2017, that its Goa plant's inspection by UK MHRA from 14 February 2017 to 17 February 2017 was completed without any critical observations.

Marksans Pharma's consolidated net profit fell 37% to Rs 11.30 crore on 1% decrease in net sales to Rs 215.24 in Q3 December 2016 over Q3 December 2015.

Marksans Pharma is a global pharmaceutical company. It is engaged in research & development (R&D) and offers CRAMS (contract research and manufacturing services) to global pharmaceutical companies.